Event-Driven Stocks

CytomX Therapeutics, Inc.

CTMXNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 5 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$76.2M$138.1M$101.2M$53.2M$37.3M$100.4M
Operating income−$22.4M$25.0M−$6.5M−$101.3M−$116.0M−$48.6M
Net income−$17.4M$31.9M−$569,000−$99.3M−$115.9M−$32.9M
Total assets$151.6M$120.5M$201.8M$260.9M$339.4M$358.7M
Total liabilities$52.6M$121.0M$249.2M$346.6M$339.9M$308.9M
Equity$99.0M−$456,000−$47.4M−$85.8M−$459,000$49.8M
EPS (diluted)——————
Shares out.170.2M67.7M66.2M65.4M64.8M45.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−29.3%
Net margin
−22.8%
Return on equity
−17.5%
Return on assets
−11.5%
Return on capital (ROCE)
−21.3%
Liabilities / assets
34.7%
Debt / equity
0.53×
Book value / share
$0.58
Revenue growth (YoY)
−44.8%
Net income growth (YoY)
−154.5%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-10.12distress
Accruals / assets
38.4%high accruals
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
22
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 5 warning● 1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202631.1M10.3+4.7%
Apr 30, 202629.7M8.4+8.1%
Apr 15, 202627.5M5.4+24.9%
Mar 31, 202622.0M1.1+7.9%
Mar 13, 202620.4M7.1+8.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.